Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc., listed under the ticker CKPT, is a pioneering immuno-oncology biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Founded in 2014 and headquartered in New York, New York, the company operates as a subsidiary of Fortress Biotech, Inc.
Checkpoint Therapeutics focuses on developing non-chemotherapy, immune-enhanced combination treatments. One of its leading product candidates is CK-101, currently in phase I clinical trials, aimed at treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Another significant candidate is Cosibelimab, a programmed death ligand-1 (PD-L1) inhibitor in phase I trials for selected recurrent or metastatic cancers.
In addition to these, Checkpoint Therapeutics is working on CK-103, a small molecule inhibitor targeting BET bromodomains, and CK-302, a human agonistic antibody designed for oncology indications. The company has also developed a strong portfolio of antibodies focusing on PD-L1, GITR, and CAIX targets.
Checkpoint Therapeutics collaborates with TG Therapeutics, Inc. to develop and commercialize specific assets in hematological malignancies. This partnership underscores the company's commitment to advancing cancer therapies through strategic alliances.
Checkpoint Therapeutics' robust pipeline, innovative approaches to cancer treatment, and strategic collaborations make it a significant player in the biopharmaceutical industry. Investors and stakeholders can look forward to the company's continuous advancements and contributions to oncology.
Checkpoint Therapeutics (NASDAQ: CKPT) announced the formation of an independent Scientific Advisory Board featuring leading experts in oncology. This board will collaborate with Checkpoint's leadership to advance novel cancer treatments, specifically cosibelimab for skin and lung cancers, and CK-101 for lung cancer. Notable members include prominent figures from Harvard Medical School and Dana-Farber Cancer Institute. CEO James F. Oliviero expressed confidence in their impactful contributions to the company's mission of developing life-saving cancer therapies.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in three virtual investor conferences in January 2021. The events include the 10th Annual LifeSci Partners Corporate Access Event, where one-on-one meetings will occur from January 6-14. The H.C. Wainwright Virtual BioConnect Conference will feature an on-demand presentation starting January 11. Lastly, B. Riley Securities' Virtual Oncology Investor Conference presentation is set for January 21. Webcasts for select presentations will be available for 30 days on Checkpoint's website.
Checkpoint Therapeutics (CKPT) reported Q3 2020 financial results, highlighting positive interim outcomes from its clinical trial of cosibelimab for metastatic cutaneous squamous cell carcinoma (mCSCC). The company aims to complete enrollment for this trial by early 2021 and expects to release top-line results later in the year. Checkpoint expanded its cash runway with a $20.5 million financing, increasing cash reserves to $42 million. R&D expenses decreased to $2.5 million, while net loss narrowed to $4.9 million, or $0.09 per share, compared to the previous year's loss.
Samsung Biologics and Checkpoint Therapeutics have expanded their manufacturing partnership for the anti-PD-L1 antibody, cosibelimab, originally established in 2017. Under the new agreement, commercial-scale drug substance manufacturing will commence at Samsung's Plant 1 in 2021. This partnership aims to support Checkpoint's pivotal clinical trials and potential regulatory approvals for cosibelimab, which targets metastatic cutaneous squamous cell carcinoma. Checkpoint plans to release pivotal trial topline results by mid-2021.
Checkpoint Therapeutics (NASDAQ: CKPT) announced an underwriting agreement with H.C. Wainwright & Co. to sell 7,142,857 shares of common stock at $2.80 per share, expecting gross proceeds of $20 million. The offering's closing is anticipated around September 22, 2020, pending customary conditions. Additionally, the underwriter has a 30-day option to purchase up to 1,071,428 additional shares. Funds from the offering will support development activities for cosibelimab and other corporate needs.
Checkpoint Therapeutics (CKPT) announced interim results for cosibelimab, an anti-PD-L1 antibody targeting metastatic cutaneous squamous cell carcinoma (mCSCC). The data showed a 51.4% objective response rate (ORR) and 13.5% complete response rate, exceeding previous anti-PD-1 therapies. A favorable safety profile was noted, with lower severe adverse events. The company aims for market-disruptive pricing in the estimated $25 billion PD-(L)1 market. Full results are expected mid-2021, emphasizing the potential for cosibelimab to provide cost-effective treatment options.
Checkpoint Therapeutics (NASDAQ: CKPT) has announced the participation of President and CEO James F. Oliviero in three virtual investor conferences in September 2020. The events include:
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 p.m. EDT
- Cantor Virtual Global Healthcare Conference on September 16, 2020, at 10:00 a.m. EDT
- Lake Street Capital Markets 4th Annual Best Ideas Growth Conference on September 17, 2020
Webcasts will be available on Checkpoint’s website for approximately 30 days post-event.
Checkpoint Therapeutics (NASDAQ: CKPT) reported its Q2 financial results on August 5, 2020.
As of June 30, 2020, the company had cash and cash equivalents of $21.9 million, down from $26.1 million at the end of 2019. R&D expenses decreased to $3.0 million from $4.1 million in 2019.
Despite a net loss of $4.6 million, improving from a loss of $4.8 million in Q2 2019, Checkpoint continues to advance its anti-PD-L1 antibody cosibelimab, with enrollment at over 50% for its pivotal trial in metastatic cutaneous squamous cell carcinoma.
Checkpoint Therapeutics (CKPT) announced updated interim data on cosibelimab for metastatic cutaneous squamous cell carcinoma (mCSCC) ahead of its presentation at the ESMO Virtual Congress 2020. Over 50% of the enrollment target has been achieved, with completion expected by year-end. Cosibelimab, a high-affinity anti-PD-L1 antibody, aims to disrupt the $25 billion PD-(L)1 therapy market with competitive pricing. The company expects to share full top-line results next year for this promising therapy, which currently has a 50% objective response rate among initial patients.
FAQ
What is the current stock price of Checkpoint Therapeutics (CKPT)?
What is the market cap of Checkpoint Therapeutics (CKPT)?
What does Checkpoint Therapeutics, Inc. specialize in?
What are the key products in Checkpoint Therapeutics' pipeline?
Where is Checkpoint Therapeutics headquartered?
When was Checkpoint Therapeutics founded?
What strategic partnerships does Checkpoint Therapeutics have?
What is Cosibelimab?
What stage is CK-101 in?
Who is the parent company of Checkpoint Therapeutics?
What types of cancers is Checkpoint Therapeutics focusing on?
Does Checkpoint Therapeutics have any small molecule inhibitors in development?
